Carfilzomib

• MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending
  2024-513889-19-00 Phase III 2 countries Intergroupe Francophone Du Myelome
• Daratumumab in Combination with Carfilzomib, Pomalidomide and Dexamethasone in patients with myeloma induced acute renal failure Pending
  2024-514702-31-00 Phase II 1 country Medizinische Universitaet Innsbruck
• Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM): A nationwide phase 2 trial of patients with smoldering and active multiple my… Pending
  2024-519353-11-00 Phase II 1 country Landspitali
• A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending
  2024-519504-27-00 Phase III 10 countries Regeneron Pharmaceuticals Inc.
• A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refrac… Pending
  2025-521090-14-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. Pending
  2025-523285-25-00 Phase III 6 countries AstraZeneca AB
• A study investigating the safety and efficacy of academically-produced CAR T cells compared with standard treatment for patients with multip… Pending
  2025-524876-43-00 Phase III 1 country Universitair Medisch Centrum Groningen
• A study to evaluate the efficacy and safety of belantamab mafodotin in combination with standard of care in participants aged 18 years and o… Recruiting
  2025-523117-28-00 Phase II 5 countries Glaxosmithkline Research & Development Limited
• A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants with Multiple Myeloma Receiving Etentamig (ABBV-… Recruiting
  2024-515770-27-00 Phase I/II 1 country AbbVie Deutschland GmbH & Co. KG
• A Phase 3 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and Exposed to Lenalido… Recruiting
  2024-515279-37-00 Phase III 17 countries Celgene Corp.
• A Phase 1b/2 Study of BGB-11417 as Monotherapy and in Various Combinations with Dexamethasone plus Carfilzomib, Dexamethasone plus Daratumum… Recruiting
  2023-507751-30-00 Phase I/II 5 countries BeOne Medicines AG
• C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL… Recruiting
  2023-507871-23-00 Phase III 16 countries Pfizer Inc.
• Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma Ended
  2024-511188-26-00 Phase III 9 countries Kite Pharma Inc.
• RElapse from Mrd Negativity As iNdication for Treatment Ended
  2023-510215-18-00 Phase II/III 2 countries Oslo University Hospital HF
• A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot… Ended
  2023-506668-15-00 Phase III 13 countries AbbVie Deutschland GmbH & Co. KG
• International treatment-extension study in adult participants with multiple myeloma and who have derived clinical benefit from isatuximab Ended
  2023-507180-19-00 Phase II 7 countries Sanofi-Aventis Recherche & Developpement
• A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas… Ended
  2023-503444-13-00 Phase III 13 countries Janssen - Cilag International
• A Clinical Study to evaluate the long-term safety of Daratumumab in combination with standard bone marrow cancer treatment regiments Ended
  2022-500138-27-01 Phase III 9 countries Janssen - Cilag International
• Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Mult… Ended
  2022-500861-29-00 Phase III 11 countries Celgene Corp.
• A study to investigate subcutaneous isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or … Ended
  2023-508870-27-00 Phase II 3 countries Sanofi-Aventis Recherche & Developpement
• An open label, multicenter, phase I/II study of belantamab mafodotin in combination with Kd for the treatment of relapsed myeloma patients, … Ended
  2024-517006-28-00 Phase I/II 1 country Fundacion PETHEMA
• Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) Ended
  2024-511929-60-00 Phase II 3 countries Universitaetsklinikum Ulm AöR
• A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refra… Ended
  2023-505659-27-00 Phase II 2 countries AbbVie Deutschland GmbH & Co. KG
• A Clinical trial to compare the combination of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone versus the combination of Carfilzomib-Lenal… Ended
  2024-513422-38-00 Phase III 8 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.

Showing 1–24 of 38 trials